Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
A mid-stage study of enfortumab illustrates the relevance of nectin-4 in urothelial bladder cancer, and is hailed by experts as registrational.
Fibrogen tumbles on a confusing safety update for its most advanced project.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.